To evaluate the efficacy of tofacitinib in patients with calcinosis cutis associated with juvenile dermatomyositis.
Approach:
Primary Outcome: The primary outcome is the impact of tofacitinib on the burden of calcinosis cutis, assessed by the Agatston score from CT scans at 6 months.
Secondary Outcomes: Secondary outcomes include effects on the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Childhood Myositis Assessment Scale (CMAS), steroid dosage, type I interferon levels, and monitoring of adverse events.
Key Findings:
Tofacitinib was administered based on weight bands, with dosages ranging from 3.2 mg to 5 mg twice daily. The study aimed for a sample size of 20 participants to achieve an 80% power to detect a 50% reduction in the Agatston score.
Interpretation:
The study is designed to provide insights into the efficacy of tofacitinib for managing calcinosis cutis in juvenile dermatomyositis, addressing a significant treatment gap.
Limitations:
Open-label design may introduce bias.
Limited sample size may affect generalizability.
Conclusion:
The study aims to assess the efficacy of tofacitinib for calcinosis cutis in juvenile dermatomyositis, with results expected to enhance understanding of management strategies.
